|
1）Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature. 1953; 171: 737-8
|
|
|
|
2）The FANTOM Consortium: The transcriptional landscape of the mammalian genome. Science. 2005; 309: 1559-63
|
|
|
|
|
|
3）RIKEN Genome Exploration Group and Genome Science Group. Antisense transcription in the mammalian transcriptome. Science. 2005; 309: 1564-6
|
|
|
|
|
|
4）Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature. 1998; 391: 806-11
|
|
|
|
|
|
5）Elbashir S, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411: 494-8
|
|
|
|
|
|
6）Grimm D, Steetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006; 441: 537-41
|
|
|
|
|
|
7）John M, Constien R, Akinc A, et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature. 2007; 449: 745-7
|
|
|
|
|
|
8）Fattal E, Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev. 2006; 58: 1203-23
|
|
|
|
|
|
9）Fujita Y, Kuwano K, Ochiya T. Development of small RNA delivery systems for lung cancer therapy. Int J Mol Sci. 2015; 16: 5254-70
|
|
|
|
|
|
10）Merkel OM, Rubinstein I, Kissel T. siRNA delivery to the lung: what's new? Adv Drug Deliv Rev. 2014; 75: 112-28
|
|
|
|
|
|
11）Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003; 31: 2705-16
|
|
|
|
|
|
12）Ui-Tei K, Naito Y, Zenno S, et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008; 36: 2136-51
|
|
|
|
|
|
13）Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev. 2012: 64: 1-15
|
|
|
|
|
|
14）Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015; 16: 543-52
|
|
|
|
|
|
15）Coelho T, Adams D, Silva A, et al. safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369: 819-29
|
|
|
|
|
|
16）Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type9（PCK9） and the concentration of serum LDL cholesterol in healty volunteers: a randomized, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014; 383: 60-8
|
|
|
|
|
|
17）Fernandez IE, Eickelberg O. The impact of TGF-β on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012; 9: 111-6
|
|
|
|
|
|
18）Warburton D, Shi W, Xu B. TGF-β-Smad3 signaling in emphysema and pulmonary fibrosis: an epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol. 2013; 304: L83-5
|
|
|
|
|
|
19）D’Alessandro-Gabazza CN, Kobayashi T, Boveda-Ruiz D, et al. Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012; 46: 397-406
|
|
|
|
|
|
20）Hamasaki T, Suzuki H, Shirohzu H, et al. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One. 2012; 7: e42655
|
|
|
|
|